ArticleAmerican journal of translational research2026
Differences in immunity and survival among non-small cell lung cancer patients: a gut microbiota perspective.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the relationship between key gut microbiota [Enterococcus, Escherichia coli (E. coli), Bifidobacterium, and Lactobacillus] and immune function in Chinese patients with non-small cell lung cancer (NSCLC).
methodsThis study included 208 patients with NSCLC enrolled between March 2021 and June 2023. Fecal samples were collected from patients for quantitative analysis of Enterococcus, E. coli, Bifidobacterium, and Lactobacillus. Additionally, peripheral blood samples were collected from patients, and levels of T lymphocyte subsets (CD3
resultsIn the immune checkpoint inhibitor (ICI) responders (R group), higher proportions of Bifidobacteria and Lactobacilli were observed, whereas non-responders (NR group) exhibited increased proportions of Enterococcus and E. coli. Furthermore, Bifidobacteria and Lactobacilli showed positive correlations with T cell counts but negative correlations with inflammatory cytokine levels. Opposing relationships were seen for Enterococcus and E. coli, which correlated negatively with T cells and positively with IL-6 and TNF-α (P < 0.05).
conclusionIn NSCLC, Bifidobacterium and Lactobacillus promote beneficial immune feedback loops by activating T cells and exerting anti-inflammatory effects, thereby supporting antitumor immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.